Davenport & Co’s Cue Biopharma CUE Stock Holding History

Davenport & Co’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-427	Closed	-$160K	–	812
2020 Q4	$160K	Buy	+427	New	+$171K	﹤0.01%	752

Other funds holding CUE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Davenport & Co's CUE Position: Q1 2021 in Review

Davenport & Co sold out of Cue Biopharma (CUE) in Q1 2021, closing a stake of 427 shares — an estimated $160K sold.

Davenport & Co first reported a position in CUE in Q4 2020 and held it in 1 quarter. The position peaked at $160K in Q4 2020. 89 funds tracked by Wall St. Rank hold CUE as of Q1 2021.

Davenport & Co reported no remaining Cue Biopharma position as of Q1 2021 after selling out during the quarter.
Davenport & Co sold 427 Cue Biopharma shares in Q1 2021, an estimated $160K.
Davenport & Co first reported a position in Cue Biopharma in Q4 2020 and held it in 1 quarter.
Davenport & Co's Cue Biopharma position peaked at $160K in Q4 2020.
89 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2021.

Based on Davenport & Co's 13F filing for Q1 2021, filed 28 Apr 2021.